Femasys Inc (FEMY) Stock Price, Quote & News

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 770 500 3910

Fax: 404 581 5903

Website: www.femasys.com

Address:

3950 Johns Creek Court, Suite 100, Suwanee, United States

ZeroJobZeroProblem Dec. 4 at 7:40 PM

$FEMY StockTwits sentiment is broken... unless someone is going back to an old post and just posting like 100x on some old post with bearish posts and we are not seeing it. ALL of the posts in the last 24 hours is BULLISH and it shows we are 37% bearish... What the hell?

0 · Reply

Alican1994 Dec. 4 at 5:28 PM

$FEMY Pinga grande para arriba F the Shorty 🙏👌💪🥃

0 · Reply

rastamfjones Dec. 4 at 4:57 PM

$FEMY knock knock knocking on heaven’s door!

1 · Reply

goldenxb Dec. 4 at 4:47 PM

$FEMY yesssss let’s go

0 · Reply

Alican1994 Dec. 4 at 4:40 PM

$FEMY

0 · Reply

Alican1994 Dec. 4 at 4:39 PM

$FEMY Pinga dura y para arriba

0 · Reply

4RiskyBusiness4 Dec. 4 at 4:04 PM

$FEMY Glad I added on that recent dip.

1 · Reply

harambe_reborn Dec. 4 at 3:26 PM

$FEMY trump admin openly pushing for more babies in the US while providing financial support for increased access to fertility care operation moonshot 2.0 here

0 · Reply

UntamedPotato Dec. 4 at 3:23 PM

$FEMY

0 · Reply

goldenxb Dec. 4 at 3:11 PM

$FEMY

0 · Reply

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

Nov 3, 2025, 8:30 AM EST - 4 weeks ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Oct 16, 2025, 9:00 AM EDT - 7 weeks ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Sep 11, 2025, 9:00 AM EDT - 3 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 8, 2025, 9:00 AM EDT - 3 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Aug 25, 2025, 11:44 PM EDT - 3 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 8, 2025, 5:22 PM EDT - 4 months ago

Femasys Revenue Jumps 85 Percent in Q2

Aug 8, 2025, 4:05 PM EDT - 4 months ago

Femasys Announces Second Quarter Financial Results for 2025

Aug 6, 2025, 9:00 AM EDT - 4 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Jul 1, 2025, 9:00 AM EDT - 5 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jun 25, 2025, 9:00 AM EDT - 5 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 17, 2025, 9:00 AM EDT - 6 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 11, 2025, 9:00 AM EDT - 6 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

May 29, 2025, 4:23 PM EDT - 6 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 8, 2025, 5:01 PM EDT - 7 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 9 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 19, 2025, 9:20 AM EDT - 9 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 18, 2025, 9:00 AM EDT - 9 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 13, 2025, 8:30 AM EDT - 9 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Feb 25, 2025, 9:20 AM EST - 10 months ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025, 9:00 AM EST - 10 months ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Jan 30, 2025, 8:30 AM EST - 11 months ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025, 8:30 AM EST - 11 months ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 6, 2024, 9:00 AM EST - 1 year ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Feb 28, 2024, 9:00 AM EST - 1 year ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 6, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Jan 26, 2024, 8:00 AM EST - 2 years ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Jan 23, 2024, 8:30 AM EST - 2 years ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

ZeroJobZeroProblem Dec. 4 at 7:40 PM

0 · Reply

Alican1994 Dec. 4 at 5:28 PM

$FEMY Pinga grande para arriba F the Shorty 🙏👌💪🥃

0 · Reply

rastamfjones Dec. 4 at 4:57 PM

$FEMY knock knock knocking on heaven’s door!

1 · Reply

goldenxb Dec. 4 at 4:47 PM

$FEMY yesssss let’s go

0 · Reply

Alican1994 Dec. 4 at 4:40 PM

$FEMY

0 · Reply

Alican1994 Dec. 4 at 4:39 PM

$FEMY Pinga dura y para arriba

0 · Reply

4RiskyBusiness4 Dec. 4 at 4:04 PM

$FEMY Glad I added on that recent dip.

1 · Reply

harambe_reborn Dec. 4 at 3:26 PM

$FEMY trump admin openly pushing for more babies in the US while providing financial support for increased access to fertility care operation moonshot 2.0 here

0 · Reply

UntamedPotato Dec. 4 at 3:23 PM

$FEMY

0 · Reply

goldenxb Dec. 4 at 3:11 PM

$FEMY

0 · Reply

steve04240 Dec. 4 at 3:03 PM

$FEMY looking good

0 · Reply

Mirto Dec. 4 at 2:07 PM

$FEMY good ol’ Kathy Septic Tank relying on stealing more hard earned money from long term believers while shorts and flipping dorks have their way with her company. New CEO yet? What a joke.

1 · Reply

BullishDaddybear Dec. 4 at 12:49 AM

$FEMY The whole market has been down the last almost 10 days and actually short term almost the last month and we have went from $0.80-$1.05 and is consolidating.. and after consolidating comes That’s right — after consolidation, the next phase is usually called: ➡️ A Breakout.!! Breakout = price moves up out of the consolidation range. Simple explanation: • Consolidation = price moving sideways in a tight range (pennies up/down) THEN !!• Breakout = buyers take control → price moves sharply up

0 · Reply

sk7777777 Dec. 3 at 10:49 PM

$FEMY Almost finished simmering. It will be ready soon.

0 · Reply

wolfden2000 Dec. 3 at 8:40 PM

$FEMY could be bottom with full reversal. Looks that way.

0 · Reply

goldenxb Dec. 3 at 8:13 PM

$FEMY would be cool to close green but either way, progress in the right direction since the morning

2 · Reply

Mazen79 Dec. 3 at 5:01 PM

$FEMY 0.4 again

2 · Reply

4RiskyBusiness4 Dec. 3 at 4:59 PM

$FEMY Apparently unlimited shares for sale at .85-ish. 🤪

0 · Reply

goldenxb Dec. 3 at 3:43 PM

$FEMY reversal soon 🙂

0 · Reply

David_M_ Dec. 3 at 3:11 PM

$FEMY

0 · Reply

TripTrap Dec. 3 at 3:04 PM

$FEMY Patience is what separates the men from the boys… This is not an easy time for us. If you want a lesson in patience… I watched “The Big Short” last night… extremely smart gutsy guys shorted the housing market too early … but they knew they were right. Same here… we know we’re right being long on FEMY… We’re just early and it’s frustrating as hell but I will continue to do other things in life for the time being and sit on my hands and wait this out! 💪

1 · Reply

Trissy08 Dec. 3 at 2:52 PM

$FEMY disappointing couple of days. Was sure we were going to push on and stay above $1 then kick on

0 · Reply

Market Cap	52.05M
Revenue (ttm)	1.63M
Net Income (ttm)	-18.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,154.60%
Debt to Equity Ratio	0.02

Volume	1,341,800
Avg Vol	9,904,402
Day's Range	N/A - N/A
Shares Out	58.48M
Stochastic %K	39%
Beta	-2.59
Analysts	Strong Sell
Price Target	$5.67